Online inquiry

IVTScrip™ mRNA-Anti-APP, BART(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3525MR)

This product GTTS-WQ3525MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, BART(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3525MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1240MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-165
GTTS-WQ11170MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MDX-1333
GTTS-WQ1740MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301
GTTS-WQ12480MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ1396MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ4000MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ13054MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ9092MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMCgp100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW